Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the American Association for the study of liver diseases and the European Association for the study of the liver. Hepatology 2014 Aug;60(2):715-735.
The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nat Rev Gastroenterol Hepatol 2013 Sep;10(9):522-528.
Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations. Hepatology 1998 Nov;28(5):1215-1225.
Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J Gastroenterol Hepatol 2001 May;16(5):531-535.
Critical flicker frequency for quantification of low-grade hepatic encephalopathy. Hepatology 2002 Feb;35(2):357-366.
Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. Hepatology 2007 Apr;45(4):879-885.
The Stroop smartphone application is a short and valid method to screen for minimal hepatic encephalopathy. Hepatology 2013 Sep;58(3):1122-1132.
Diagnosis of minimal hepatic encephalopathy using StroopEncephalApp: a multicenter US-based, norm-based study. Am J Gastroenterol 2016 Jan;111(1):78-86.
Prospective comparative study of inhibitory control test and psychometric hepatic encephalopathy score for diagnosis and prognosis of minimal hepatic encephalopathy in cirrhotic patients in the Indian subcontinent. J Dig Dis 2015 Jul;16(7):400-407.
International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN). Review article: the design of clinical trials in hepatic encephalopathy – an international society for hepatic encephalopathy and nitrogen metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011 Apr;33(7):739-747.
Clinical scenarios for the use of S100β as a marker of hepatic encephalopathy. World J Gastroenterol 2016 May;22(17):4397-4402.
Is cognitive impairment in cirrhotic patients due to increased peroxynitrite and oxidative stress? Antioxid Redox Signal 2015 Apr;22(10):871-877.
Nonabsorbable disaccharides for hepatic encephalopathy: a systematic review and meta-analysis. Hepatology 2016 Sep;64(3):908-922.
Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010 Mar;362(12):1071-1081.
Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. Gastroenterology 2014 Dec;147(6):1327-1337.
The effects of probiotics and symbiotics on risk factors for hepatic encephalopathy: a systematic review. J Clin Gastroenterol 2017;51(4):312-323.
Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J Hepatol 1998 May;28(5):856-864.
The nutritional management of hepatic encephalopathy in patients with cirrhosis: international society for hepatic encephalopathy and nitrogen metabolism consensus. Hepatology 2013 Jul;58(1):325-336.
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology 2013 Jun;57(6):2448-2457.
Lactulose improves cognitive functions and health-related quality of life in cirrhotic patients with minimal hepatic encephalopathy. Hepatology 2007 Mar;45(3):549-559.
Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). Am J Gastroenterol 2011 Feb;106(2):307-316.
Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997 Jun;25(6):1351-1360.
Comparative effectiveness of different pharmacological interventions for the treatment of minimal hepatic encephalopathy: a systematic review with network meta-analysis. Hepatology 2016 Jul;64(Suppl 1):S54.
Managing encephalopathy in the outpatient setting. Clin Liver Dis 2016 Dec;8(6):150-155.